AVGO
Broadcom
-- 180.660 TSLA
Tesla
-- 418.100 NVDA
NVIDIA
-- 137.340 PLTR
Palantir
-- 73.200 AMD
Advanced Micro Devices
-- 130.600 
NEWS
SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications
Wednesday, 11th December at 6:30 am
U.S. total addressable market for five initial indications is $25 to $33 billion
REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today
DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device (SCD) in five clinical indications, subject to U.S. Food & Drug Administration (FDA) approvals, of $25 to $33 billion.
Wednesday, 11th December at 6:30 am
U.S. total addressable market for five initial indications is $25 to $33 billion
REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today
DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device (SCD) in five clinical indications, subject to U.S. Food & Drug Administration (FDA) approvals, of $25 to $33 billion.
The SCD has been awarded FDA Breakthrough Device Designation (BDD) in three of the five indications included in the chart above, namely adult AKI, hepatorenal syndrome and cardiorenal syndrome with LVAD. The SCD was also awarded BDD for chronic dialysis in November 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment